分组1 - Sensata reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.86 per share, and up from $0.76 per share a year ago [1] - The company achieved revenues of $917.9 million for the quarter, surpassing the Zacks Consensus Estimate by 1.22% and increasing from $907.69 million year-over-year [3] - Sensata has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2][3] 分组2 - The stock has gained approximately 10.1% since the beginning of the year, compared to a 0.5% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.83, with expected revenues of $928.78 million, and for the current fiscal year, the EPS estimate is $3.63 on revenues of $3.79 billion [8] - The Instruments - Control industry, to which Sensata belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges ahead [9]

分组1 - Chemours reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of breakeven, but down from $0.11 per share a year ago, representing an earnings surprise of +2,400.00% [1] - The company posted revenues of $1.33 billion for the quarter ended December 2025, aligning with the Zacks Consensus Estimate, but down from $1.36 billion year-over-year [2] - Chemours shares have increased approximately 79.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $1.43 billion, and for the current fiscal year, it is $1.70 on revenues of $6.04 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 23% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Chemours was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Workiva (WK) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +15.56%. A quarter ago, it was expected that this maker of software for managing regulatory filings would post earnings of $0.38 per share when it actually produced earnings of $0.55, delivering a surprise of +44.74%.Over th ...

Valaris Limited (VAL) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $1.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +54.90%. A quarter ago, it was expected that this company would post earnings of $1 per share when it actually produced earnings of $2.65, delivering a surprise of +165%.Over the last four quarters, the company has ...

ICU Medical (ICUI) came out with quarterly earnings of $1.91 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $2.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +13.52%. A quarter ago, it was expected that this medical device maker would post earnings of $1.54 per share when it actually produced earnings of $2.03, delivering a surprise of +31.82%.Over the last four quarters, t ...

Consolidated Edison (ED) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.59%. A quarter ago, it was expected that this utility would post earnings of $1.76 per share when it actually produced earnings of $1.9, delivering a surprise of +7.95%.Over the last four quarters, the company ...

Axon Enterprise (AXON) closed at $441.12 in the latest trading session, marking a +2.56% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.54%, while the tech-heavy Nasdaq depreciated by 0.31%. Shares of the maker of stun guns and body cameras witnessed a loss of 29.52% over the previous month, trailing the performance of the Aerospace sector with its loss of 2.29%, and the S&P 500's loss of 0.76%.The investment community wil ...

Financial Performance - Pulse Biosciences reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of +18.75% [1] - The company posted revenues of $0.26 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.60%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on $0.5 million in revenues, and for the current fiscal year, it is -$1.66 on $3.75 million in revenues [7] Stock Performance - Pulse Biosciences shares have increased by approximately 85.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Pulse Biosciences belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

分组1 - AXT reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, representing an earnings surprise of -15.47% [1] - The company posted revenues of $23.04 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 10.14%, compared to year-ago revenues of $25.1 million [2] - AXT shares have increased by approximately 44% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for AXT is uncertain, with current consensus EPS estimates of -$0.04 on $26.69 million in revenues for the coming quarter and -$0.01 on $122.53 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Electronics - Semiconductors is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - AXT has a Zacks Rank of 4 (Sell), suggesting that the stock is expected to underperform the market in the near future due to unfavorable estimate revisions [6]

分组1 - RE/MAX reported quarterly earnings of $0.3 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, with an earnings surprise of +7.14% [1] - The company posted revenues of $71.14 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.15%, and a decrease from year-ago revenues of $72.47 million [2] - Over the last four quarters, RE/MAX has surpassed consensus EPS estimates four times but has only topped consensus revenue estimates once [2] 分组2 - The stock has underperformed, losing about 10% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.20 on revenues of $76.55 million, and for the current fiscal year, it is $1.26 on revenues of $296.19 million [7] - The Zacks Industry Rank for Real Estate - Operations is in the bottom 39% of over 250 Zacks industries, indicating potential challenges for stock performance [8]